Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial

Anders Granholm,Marie Warrer Munch,Sheila Nainan Myatra,Bharath Kumar Tirupakuzhi Vijayaraghavan,Maria Cronhjort,Rebecka Rubenson Wahlin,Stephan M Jakob,Luca Cioccari,Maj-Brit Nørregaard Kjær,Gitte Kingo Vesterlund,Tine Sylvest Meyhoff,Marie Helleberg,Morten Hylander Møller,Thomas Benfield,Balasubramanian Venkatesh,Naomi E Hammond,Sharon Micallef,Abhinav Bassi,Oommen John,Vivekanand Jha,Klaus Tjelle Kristiansen,Charlotte Suppli Ulrik,Vibeke Lind Jørgensen,Margit Smitt,Morten H Bestle,Anne Sofie Andreasen,Lone Musaeus Poulsen,Bodil Steen Rasmussen,Anne Craveiro Brøchner,Thomas Strøm,Anders Møller,Mohd Saif Khan,Ajay Padmanaban,Jigeeshu Vasishtha Divatia,Sanjith Saseedharan,Kapil Borawake,Farhad Kapadia,Subhal Dixit,Rajesh Chawla,Urvi Shukla,Pravin Amin,Michelle S Chew,Christian Aage Wamberg,Christian Gluud,Theis Lange,Anders Perner

DOI: https://doi.org/10.1007/s00134-021-06573-1

Abstract:Purpose: We compared dexamethasone 12 versus 6 mg daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, randomised, blinded COVID STEROID 2 trial. In the primary, conventional analyses, the predefined statistical significance thresholds were not reached. We conducted a pre-planned Bayesian analysis to facilitate probabilistic interpretation. Methods: We analysed outcome data within 90 days in the intention-to-treat population (data available in 967 to 982 patients) using Bayesian models with various sensitivity analyses. Results are presented as median posterior probabilities with 95% credible intervals (CrIs) and probabilities of different effect sizes with 12 mg dexamethasone. Results: The adjusted mean difference on days alive without life support at day 28 (primary outcome) was 1.3 days (95% CrI -0.3 to 2.9; 94.2% probability of benefit). Adjusted relative risks and probabilities of benefit on serious adverse reactions was 0.85 (0.63 to 1.16; 84.1%) and on mortality 0.87 (0.73 to 1.03; 94.8%) at day 28 and 0.88 (0.75 to 1.02; 95.1%) at day 90. Probabilities of benefit on days alive without life support and days alive out of hospital at day 90 were 85 and 95.7%, respectively. Results were largely consistent across sensitivity analyses, with relatively low probabilities of clinically important harm with 12 mg on all outcomes in all analyses. Conclusion: We found high probabilities of benefit and low probabilities of clinically important harm with dexamethasone 12 mg versus 6 mg daily in patients with COVID-19 and severe hypoxaemia on all outcomes up to 90 days.